A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD).

Trial Profile

A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Study of 2 Oral Dose Groups of AZD7325, With a Lorazepam Arm, in Subjects With Generalized Anxiety Disorder (GAD).

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2010

At a glance

  • Drugs AZD 7325; Lorazepam
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Sep 2009 Actual patient number (677) added as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top